ClinicalTrials.gg
Not yet recruitingNCT07941388INT-1868-I101Updated Nov 17, 2026

A Phase I Study of INT-1868 Tablets in Healthy Adult Participants (INT-1868-I101)

A Phase 1 interventional study of INT-1868 Tablets and INT-1868 Tablets in Atopic Dermatitis (AD), sponsored by Innatus Therapeutics (Shanghai) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Innatus Therapeutics (Shanghai) Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
136th of 191
92 · median 163
Started
2026
with 32 others
Phase 1
39 of 207
15 open now
Primary completion
2027-06
later than 47 of 82 live
Registered
207th of 207
by date

Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 136th largest by planned enrollment of the 191 interventional ones that give a count, is one of 33 that started in 2026, is one of 39 in phase 1, reaches primary completion later than 47 of the 82 other live ones, and was the 207th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose escalation, and Food-Effect Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INT-1868 Tablets in Healthy Adult Participants.

  • Primary Objectives:

    1. To evaluate the safety and tolerability of INT-1868 tablets after single and multiple doses in healthy adult participants;

  • Secondary Objectives:

    1. To evaluate the PK characteristics of INT-1868 tablets after single and multiple doses in healthy adult participants; 2. To evaluate the effect of food on the PK characteristics of INT-1868 tablets;

  • Other Objectives:

    1. To evaluate the PD characteristics of INT-1868 tablets after single and multiple doses in healthy adult participants;
    2. To evaluate the PK characteristics of INT-1868 tablet metabolites (if applicable) after single and multiple doses in healthy adult participants;
    3. To assess the effect of INT-1868 tablets on C-QTc;
    4. To preliminarily evaluate the metabolic characteristics of INT-1868 tablets in humans.
03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants fully understand the purpose, nature, methods, and potential adverse reactions of the trial, voluntarily participate and sign the written Form, and are able to comply with the Protocol requirements to complete the study;
  • Healthy trial participants aged 18 to 45 years (inclusive), regardless of gender (the proportion of males and females in each group shall not be less than 1/3);
  • (BMI: weight [kg]/height [m2) between 18.5 and 26.0 kg/m2Within the range (including boundary values), participants body weight ≥45 kg for females and ≥50 kg for males;
  • The investigator determines that the participants is in good general health (assessed by medical history, surgical history, physical examination, vital signs, laboratory tests, , etc., with no evidence of active or chronic cyclic diseases);
  • Female participants of must agree to use effective throughout the study period and for at least 90 days after the last dose; all female participants must have no plan for pregnancy or egg donation from the start of the study until at least 90 days after the last dose;
  • Males of must agree to practice abstinence or use effective contraception throughout the study period and for at least 90 days after the last dose; all male trial participants must have no plan to donate sperm throughout the study period and for at least 90 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  • As assessed by the Investigator, presence ofClinically significantHistory of diseases, including but not limited to those of the gastrointestinal system, cardiovascular system, musculoskeletal system, endocrine system, blood and lymphatic system, kidneys, liver, respiratory system, nervous system, immune system, reproductive system, and lipid metabolism disorders; or any abnormal results in physical examination, vital signs, , or laboratory tests during the screening period as determined by the Investigator;
  • History of hospitalization or major surgery within the 6 months prior to screening, planned surgery during the study period, or history of bariatric surgery;
  • History of gastrointestinal, hepatic, or renal diseases that may affect drug absorption or metabolism;
  • History of hypertrophic scarring (keloid constitution), or skin abnormalities unsuitable for skin sample collection, or history of allergy to anesthetics or antibiotics (limited to trial participants intended for enrollment in the MAD study);
  • Participants with abnormal swallowing function, unable to swallow oral formulations normally;
  • During the screening period, the presence of any of the following electrocardiogram (ECG) abnormalities:

    1. Any ECG parameters outside the normal range or abnormal findings considered clinically significant by the Investigator;
    2. Any electrocardiogram (ECG) abnormalities (e.g., difficulty in measuring , conduction abnormalities) that the Investigator considers may affect the interpretation of cardiac safety and/or interfere with the assessment of adverse events after dosing;
    3. QT interval corrected by the Fridericia formula (QTcF) ≥450 ms for males and ≥460 ms for females;
  • Resting heart rate \<50 beats per minute (bpm) or >100 beats per minute (bpm) during the screening period;
  • Systolic blood pressure ≥140 mmHg or \<90 mmHg, and/or diastolic blood pressure ≥90 mmHg or \<50 mmHg during the screening period;
  • Renal function judged by the Investigator based on clinical laboratory results, with an estimated (eGFR) \<90 mL/min/1.73 m² calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation, or signs of renal impairment;
  • Presence of active liver disease or unexplained abnormalities in liver function tests (LFTs) during the screening period, defined as: (ALT), Aspartate Aminotransferase (AST), γ-Glutamyl Transferase (γ-GGT), Alkaline Phosphatase (ALP), or Total/Direct levels exceeding the Upper Limit of the Reference Range (ULRR); or participants diagnosed with Gilbert's syndrome (constitutional non-hemolytic jaundice) are not allowed to participate in the study;
  • Participants with positive results for any of the following tests: (HIV) antibody, surface antigen (HBsAg), virus (HCV) antibody, or Treponema pallidum antibody;
  • Trial participants with active tuberculosis, with positive tuberculosis screening results during the screening period (if applicable);
  • Patients with malignant tumors (including those cured after previous illness);
  • Participants who experience acute illness during the screening period;
  • Presence of clinically significant infections, known inflammatory diseases, or a history of clinically significant infections within 14 days before the first dose administration;
  • Known or suspected history of drug abuse within the 2 years prior to screening, or history of alcohol abuse within the 90 days prior to screening;
  • Daily smoking of more than 5 cigarettes within the 6 months prior to screening, and inability to stop smoking and using nicotine products throughout the trial period;
  • Positive results for alcohol testing or urine drug abuse screening during the screening period;
  • Alcohol consumption exceeding 14 units per week within the 6 months prior to screening (1 unit of alcohol ≈ 360 mL of beer, 45 mL of spirits with 40% alcohol content, or 150 mL of wine), or inability to abstain from alcohol during the trial;
  • Alcohol consumption within 72 hours prior to the first dose;
  • Participation in any clinical study of Medicinal Product, device, biologic, or other investigational formulation within 30 days prior to the first dose (or within 5 half-lives, whichever is longer, if applicable);
  • Use of any medication (including prescription drugs, over-the-counter drugs, traditional Chinese herbal medicines, etc., but excluding anesthetics and antibiotics permitted by the protocol for skin tissue sample collection in MAD study participants) or health supplements within 14 days prior to the first dose (or within 7 half-lives, whichever is longer);
  • Vaccination within 30 days prior to the first dose, or planned vaccination during the study period;
  • Consumption of food or beverages containing caffeine, xanthines, or grapefruit-related components (e.g., coffee, strong tea, chocolate, etc.) within 48 hours prior to the first dose;
  • Total blood loss or blood donation exceeding 400 mL, plasma donation, or transfusion of blood and blood components within 30 days prior to the first dose; donation of bone marrow or peripheral stem cells within 90 days prior to the first dose;
  • Poor venous access that fails to meet the requirements for Pharmacokinetics blood sample collection; history of intolerance to blood collection during previous phlebotomy or blood donation;
  • Known to INT-1868 or any of its , or a history of unexplained weight loss, food allergies, or intolerance to specific foods;
  • Females who are pregnant or lactating, or females of who have engaged in unprotected sexual intercourse within 14 days prior to the first dose, or females with a positive pregnancy test during the screening period;
  • Participants who are a member of the investigator, site personnel, sponsor staff, or their relatives;
  • Participants who are unwilling to comply with trial restrictions and related requirements (e.g., dietary , inability to adhere to the trial-specified diets, high-fat meals, etc.);
  • The investigator considers it inappropriate for the 29) participants to participate in this study due to scientific reasons, compliance reasons, subject safety, or any other reasons.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Single Ascending Dose from 2.5 mg to 300 mg

    Single Ascending Dose

    Drug: INT-1868 Tablets

  • Experimental
    Multiple Ascending Dose: 10 mg to 200mg

    QD for 14 days;

    Drug: INT-1868 Tablets

  • Experimental
    Food Effect: 100 mg

    Drug: INT-1868 Tablets

  • Placebo comparator
    Placebo

    Placebo for SAD, MAD and Food Effect

    Drug: INT-1868 Placebo

Interventions

  • DrugINT-1868 Tablets

    Escalating doses of 2.5, 10, 30, 100, 200, 300 mg of INT-1868; Single dose administration; Oral administration

  • DrugINT-1868 Tablets

    Escalating doses of 10, 30, 100 mg, 200 mg of INT-1868; QD for 14 days; Oral administration

  • DrugINT-1868 Tablets

    100 mg INT-1868; Dosing on Day 1 (first dose) and Day 11 (second dose);Oral administration

  • DrugINT-1868 Placebo

    INT-1868 Placebo;PO

06

What researchers measure

Primary outcomes

  1. Adverse events(AEs)

    The incidence, severity and types of AES

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

  2. Laboratory tests: Complete Blood Count

    Including complete blood count, blood biochemistry, coagulation function, and urinalysis

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

  3. Physical examination

    Including general condition (skin and lymph nodes), head (eyes, ears, nose, and throat), neck (thyroid gland), chest (lungs and heart), abdomen, spine and extremities, and nervous system

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

  4. Treatment-emergent potentially clinically significant abnormalities in vital signs:blood pressure (mmHg)

    Blood pressure (mmHg)

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

  5. Treatment-emergent potentially clinically significant abnormalities in vital signs:pulse rate (bpm)

    Pulse rate (bpm)

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

  6. Treatment-emergent potentially clinically significant abnormalities in vital signs: respiratory rate (brpm)

    Respiratory rate (brpm)

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

  7. Treatment-emergent potentially clinically significant abnormalities in vital signs: body temperature (℃)

    Body temperature (℃)

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

  8. The main parameters of the 12-lead electrocardiogram (ECG) examination: heart rate (bpm)

    Heart rate (bpm)

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

  9. The main parameters of the 12-lead electrocardiogram (ECG) examination: PR Interval (milliseconds)

    PR Interval (milliseconds)

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

  10. The main parameters of the 12-lead electrocardiogram (ECG) examination: QRS duration (milliseconds)

    QRS duration (milliseconds)

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

  11. The main parameters of the 12-lead electrocardiogram (ECG) examination: QT interval (milliseconds)

    QT interval (milliseconds)

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

  12. The main parameters of the 12-lead electrocardiogram (ECG) examination: QTc (milliseconds)

    QTc (milliseconds)

    Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

Secondary outcomes

  1. Pharmacokinetics parameter: Cmax of INT-1868

    Maximum plasma concentration

    Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

  2. Pharmacokinetics parameter: Tmax of INT-1868

    Time to reach maximum plasma concentration

    Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

  3. Pharmacokinetics parameter: AUC0-t of INT-1868

    Area under the concentration-time curve from time 0 to the time of the last measurable concentration (t)

    Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

  4. Pharmacokinetics parameter: AUC0-24 of INT-1868

    Area under the plasma concentration-time curve of the investigational product from 0 to 24 hours

    Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

  5. Pharmacokinetics parameter: AUC0-inf of INT-1868

    Area under the plasma concentration-time curve of the investigational product from time 0 to infinity

    Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

  6. Pharmacokinetics parameter: t1/2 of INT-1868

    Terminal elimination half-life

    Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

  7. Pharmacokinetics parameter: λz of INT-1868

    Terminal elimination rate constant

    Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

  8. Pharmacokinetics parameter: CL/F of INT-1868

    Apparent clearance

    Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

  9. Pharmacokinetics parameter: Vd/F of INT-1868

    Apparent volume of distribution

    Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

  10. Pharmacokinetics parameter: tlag of INT-1868

    Lag time

    Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

  11. Pharmacokinetics parameter: Cmin,ss of INT-1868

    Minimum plasma concentration at steady state

    Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

  12. Pharmacokinetics parameter: Cmax,ss of INT-1868

    Maximum plasma concentration at steady state

    Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

  13. Pharmacokinetics parameter: Css,avg of INT-1868

    Average plasma concentration at steady state

    Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

  14. Pharmacokinetics parameter: AUC0-t of INT-1868

    Area under the plasma concentration-time curve of the investigational product during the dosing interval (t)

    Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

  15. Pharmacokinetics parameter: Tmax of INT-1868

    Time to reach maximum plasma concentration at steady state

    Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

  16. Pharmacokinetics parameter: λz of INT-1868

    Terminal elimination rate constant

    Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

  17. Pharmacokinetics parameter: t1/2 of INT-1868

    Terminal elimination half-life

    Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours(29 blood sampling time points)

  18. Pharmacokinetics parameter: Rac(Cmax)of INT-1868

    Accumulation ratio based on Cmax

    Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

  19. Pharmacokinetics parameter: Rac(AUC)of INT-1868

    Accumulation ratio based on AUC

    Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

  20. Pharmacokinetics parameter: CLss/F of INT-1868

    Apparent clearance at steady state

    Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

  21. Pharmacokinetics parameter: Vz/F of INT-1868

    Apparent volume of distribution at steady state

    Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

  22. Urinary pharmacokinetic parameters, including Ae and CumAe0-t, Fe, and CumFe0-tand CLr

    Amount of drug excreted in urine (Ae), cumulative amount excreted in urine (CumAe0-t), urinary excretion fraction (Fe), cumulative excretion fraction (CumFe0-t) and renal clearance (CLr)

    Time frame: SAD: pre-dose (-12 to 0 hours) and post-dose 0-4 hours, 4-8 hours, 8-12 hours, 12-24 hours, 24-48 hours, and 48-72 hours.

  23. Fecal pharmacokinetic parameters, including Ae and CumAe0-t, Fe, and CumFe0-t

    Amount of drug excreted in feces (Ae), cumulative amount excreted in feces (CumAe0-t), fecal excretion fraction (Fe), and cumulative excretion fraction (CumFe0-t)

    Time frame: SAD: pre-dose (-24 to 0 hours) and post-dose 0-24 hours, 24-48 hours and 48-72 hours

Other outcomes

  1. Pharmacodynamics parameter: STAT6 of INT-1868

    Signal transducer and activator of transcription 6 (STAT6) in peripheral blood

    Time frame: SAD:pre-dose (within 1 hour) and post-dose from Day 1 to Day 14 MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 38

  2. Pharmacodynamics parameter: TARC of INT-1868

    Thymus and activation-regulated chemokine

    Time frame: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28

  3. Pharmacodynamics parameter: IgE of INT-1868

    Immunoglobulin E

    Time frame: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28

  4. Pharmacodynamics parameter: Eotaxin-3 of INT-1868

    Time frame: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28

  5. Pharmacodynamics parameter: STAT6 of INT-1868

    STAT6 in skin tissue

    Time frame: MAD: From Day-1 to Day 28

07

Study locations

1 site
  • Beijing Municipality -No. 101, Luyuan East Road, Tongzhou District, Beijing, China
    Beijing, Beijing Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 7 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 17, 2026
StartEst.
Nov 9, 2026
Primary completionEst.
Jun 17, 2027
CompletionEst.
Jul 17, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941388
Lead sponsor
Innatus Therapeutics (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 9, 2026 (estimated)
Primary completion
Jun 17, 2027 (estimated)
Completion
Jul 17, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Iris Liu
Contact
irisliu@innatustherapeutics.com
86-18513231616 ext. 86 10-82089858

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion